In a recent Phase I trial at the University of Minnesota, three patients with inoperable pancreatic cancer showed stable disease after receiving a genetically engineered virus treatment. One patient maintained disease control for 15 months. While these preliminary findings are promising, they require further investigation and detailed reporting to fully understand the treatment's effectiveness and safety. The trial aims to explore the potential of oncolytic virus therapy in targeting pancreatic cancer cells.
Key facts
- Three patients with inoperable pancreatic cancer participated in the trial.
- One patient achieved 15 months of disease control after treatment.
- The trial is registered as NCT06693986 and focuses on a modified adenovirus.
- The treatment aims to infect and destroy cancer cells while aiding immune recognition.
- Standard treatments for pancreatic cancer include chemotherapy and radiation.
A short AI summary in our own words. The reporting belongs to Hacker News — Front Page; we don't reproduce it.